Rallybio RLYB
NASDAQ RLYB
$16.76 -0.02 (-0.11%)
As of: Oct 2, 2026 · 2:05 PM EDT

Rallybio (RLYB) Accumulated Depreciation (2020 - 2022)

Updated

Rallybio's Accumulated Depreciation was $373,000 in Q4 2022, up 81.1% from $206,000 a year earlier.

Analysis

Rallybio (RLYB) Accumulated Depreciation (2020 - 2022) Analysis & Trends

  • In earlier years, Accumulated Depreciation was $206,000 in FY2021 (+112.4%) and $97,000 in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Rallybio 91.28 Mn 91.28 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 373,000.00
Dec 31, 2021 206,000.00
Dec 31, 2020 97,000.00
API Access

Rallybio Accumulated Depreciation API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-depreciation&ticker=RLYB&period=max&api_key=YOUR_API_KEY